|  Help  |  About  |  Contact Us

Search our database by keyword

Examples

  • Search this entire website. Enter identifiers, names or keywords for genes, diseases, strains, ontology terms, etc. (e.g. Pax6, Parkinson, ataxia)
  • Use OR to search for either of two terms (e.g. OR mus) or quotation marks to search for phrases (e.g. "dna binding").
  • Boolean search syntax is supported: e.g. Balb* for partial matches or mus AND NOT embryo to exclude a term

Search results 201 to 219 out of 219 for Gpr55

<< First    < Previous  |  Next >    Last >>
0.017s
Type Details Score
Publication
First Author: Alexander SP
Year: 2012
Journal: Br J Pharmacol
Title: So what do we call GPR18 now?
Volume: 165
Issue: 8
Pages: 2411-3
Publication
First Author: Davenport AP
Year: 2013
Journal: Pharmacol Rev
Title: International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands.
Volume: 65
Issue: 3
Pages: 967-86
Protein Domain
Type: Family
Description: Several 7TM receptors have been cloned but their endogenous ligands are unknown; these have been termed orphan receptors. However, recent research has identified certain pharmacological targets that could be investigated to find, for example, new potential cannabinoid receptors or channels [, , ]. GPR18 [, ], GPR55 [, ], GPR119 []show little structural similarity to CB1 and CB2 receptors, but they respond to endogenous agents analogous to the endogenous cannabinoid ligands, as well as some natural/synthetic cannabinoid receptor ligands []. However, because they do not fulfill all of the cannabinoid receptor criteria defined by IUPHAR, the classification of these proteins remains a contentious issue due to conflicting pharmacological results. As a result, they remain classified as putative endogenous agonists by IUPHAR [].This entry represents G protein-coupled receptor 18, also known as N-arachidonyl glycine receptor. It has been found to be a receptor for endogenous lipid neurotransmitters, several of which also bind to cannabinoid receptors [, , , ]. Recent research also supports the hypothesis that GPR18 is the abnormal cannabidiol receptor and N-arachidonoyl glycine, the endogenous lipid metabolite of anandamide, initiates directed microglial migration in the CNS through activation of GPR18 []. However, the pairing of GPR18 with N-arachidonoylglycine (NAGly) and tetrahydrocannabinol (THC) was not reproduced in two studies based on beta-arrestin assays [, ]. So, until further research allows a more definitive decision the function and nomenclature GPR18 is still being debated [, ].
Publication
First Author: Briand-Mésange F
Year: 2020
Journal: J Biol Chem
Title: Glycerophosphodiesterase 3 (GDE3) is a lysophosphatidylinositol-specific ectophospholipase C acting as an endocannabinoid signaling switch.
Volume: 295
Issue: 46
Pages: 15767-15781
Publication
First Author: Kaplan JS
Year: 2017
Journal: Proc Natl Acad Sci U S A
Title: Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome.
Volume: 114
Issue: 42
Pages: 11229-11234
Publication  
First Author: Taylor L
Year: 2015
Journal: Sci Rep
Title: Primary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB2 Receptor.
Volume: 5
Pages: 10682
Publication
First Author: Arifin SA
Year: 2018
Journal: Biochim Biophys Acta Mol Cell Biol Lipids
Title: Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119.
Volume: 1863
Issue: 9
Pages: 1132-1141
Publication
First Author: Soga T
Year: 2005
Journal: Biochem Biophys Res Commun
Title: Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor.
Volume: 326
Issue: 4
Pages: 744-51
Publication
First Author: Chu ZL
Year: 2007
Journal: Endocrinology
Title: A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
Volume: 148
Issue: 6
Pages: 2601-9
Publication
First Author: Overton HA
Year: 2006
Journal: Cell Metab
Title: Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents.
Volume: 3
Issue: 3
Pages: 167-75
Publication
First Author: Ning Y
Year: 2008
Journal: Br J Pharmacol
Title: Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells.
Volume: 155
Issue: 7
Pages: 1056-65
Publication
First Author: Swaminath G
Year: 2008
Journal: Arch Pharm (Weinheim)
Title: Fatty acid binding receptors and their physiological role in type 2 diabetes.
Volume: 341
Issue: 12
Pages: 753-61
Publication
First Author: Lan H
Year: 2009
Journal: J Endocrinol
Title: GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis.
Volume: 201
Issue: 2
Pages: 219-30
Publication  
First Author: Overton HA
Year: 2008
Journal: Br J Pharmacol
Title: GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
Volume: 153 Suppl 1
Pages: S76-81
Publication
First Author: Chu ZL
Year: 2010
Journal: Mol Endocrinol
Title: N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.
Volume: 24
Issue: 1
Pages: 161-70
Protein Domain
Type: Family
Description: Several 7TM receptors have been cloned but their endogenous ligands are unknown; these have been termed orphan receptors. However, recent research has identified certain pharmacological targets that could be investigated to find, for example, new potential cannabinoid receptors or channels [, , ]. GPR18 [, ], GPR55 [, ], GPR119 []show little structural similarity to CB1 and CB2 receptors, but they respond to endogenous agents analogous to the endogenous cannabinoid ligands, as well as some natural/synthetic cannabinoid receptor ligands []. However, because they do not fulfill all of the cannabinoid receptor criteria defined by IUPHAR, the classification of these proteins remains a contentious issue due to conflicting pharmacological results. As a result, they remain classified as putative endogenous agonists by IUPHAR [].This entry represents glucose-dependent insulinotropic receptor, also known as G protein-coupled receptor 119. It is expressed predominantly in the pancreas and gastrointestinal tract in rodents and humans, as well as in the brain in rodents []. It has been shown to be involved in the control of glucose-dependent insulin release and glucagon-like peptide 1 release, respectively [, ], which caused a reduction in food intake and body weight gain in rats []. GPR119 has also been shown to regulate incretin and insulin hormone secretion [, , ], behaving as a glucose-dependent insulinotropic receptor. As a result, new drugs acting on the receptor have been suggested as novel treatments for obesity and diabetes [, , ]. Although GPR119 is phylogenetically related to cannabinoid receptors, only fatty acid amides interact with GPR119 [, , , ]. The potency order is N-oleoyl dopamine >oleoyl ethanolamide >palmitoyl ethanolamide >anandamide [, ]. However, because only N-oleoyl dopamine and oleoyl ethanolamide have reasonably high (low micromolar) affinity for GPR119, and because neither of these lipids interacts with CB1 or CB2 receptors, GPR119 cannot currently be viewed as a cannabinoid receptor [].
Publication
First Author: Harada K
Year: 2017
Journal: J Biol Chem
Title: Lysophosphatidylinositol-induced activation of the cation channel TRPV2 triggers glucagon-like peptide-1 secretion in enteroendocrine L cells.
Volume: 292
Issue: 26
Pages: 10855-10864
Protein
Organism: Mus musculus/domesticus
Length: 331  
Fragment?: false
Protein
Organism: Mus musculus/domesticus
Length: 335  
Fragment?: false